The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT

IF 4.5 2区医学 Q1 HEMATOLOGY

Bone Marrow Transplantation Pub Date : 2025-02-12 DOI:10.1038/s41409-025-02524-2

Jakob R. Passweg, Helen Baldomero, Marina Atlija, Iliana Kleovoulou, Aleksandra Witaszek, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Fabio Ciceri, Raffaella Greco, Mette D. Hazenberg, Krzysztof Kalwak, Donal P. McLornan, Bénédicte Neven, Zinaida Perić, Antonio M. Risitano, Annalisa Ruggeri, Isabel Sánchez-Ortega, John A. Snowden, Anna Sureda

{"title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT","authors":"Jakob R. Passweg, Helen Baldomero, Marina Atlija, Iliana Kleovoulou, Aleksandra Witaszek, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Fabio Ciceri, Raffaella Greco, Mette D. Hazenberg, Krzysztof Kalwak, Donal P. McLornan, Bénédicte Neven, Zinaida Perić, Antonio M. Risitano, Annalisa Ruggeri, Isabel Sánchez-Ortega, John A. Snowden, Anna Sureda","doi":"10.1038/s41409-025-02524-2","DOIUrl":null,"url":null,"abstract":"In 2023, 47,731 HCT (20,485 (42.9%) allogeneic and 27,246 (57.1%) autologous) in 43,902 patients were reported by 696 European centers. 6042 patients received advanced cellular therapies, 4888 of which were CAR-T. Compared to the previous year there was an increase in CAR-T (+52.5%), in allogeneic HCT (+7.8%) but none in autologous HCT (+0.4%). Main indications for allogeneic HCT were myeloid (11,748; 60.7%), lymphoid malignancies (4,850; 25.0%), and non-malignant disorders (2558; 13.2%). Use of allogeneic HCT increased for AML (+12.1%) and for NHL (+11.0%), particularly in T-NHL (+25.6%). Main indications for autologous HCT were lymphomas (7890; 32.2%), PCD (14,271; 58.2%), and solid tumors (1608; 6.6%) with recovering numbers for autoimmune diseases. In patients with allogeneic HCT, the use of sibling donors increased by +1.0%, haploidentical donors by +11.7%, and unrelated donors by +11.1%. Cord blood HCT decreased again by −5.4%. Pediatric HCT activity increased slightly (5455; +0.1%) with differences between allogeneic (4111; −0.5%) and autologous HCT (1344: +1.7%). Use of CAR-T increased to a cumulative total of 13,927 patients including patients treated for autoimmune diseases. Overall, numbers show a complete recovery from the pandemic dip with increased cellular therapy at the expense of autologous HCT. Allogeneic HCT activity focuses on myeloid malignancies.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 4","pages":"519-528"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41409-025-02524-2.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Marrow Transplantation","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41409-025-02524-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In 2023, 47,731 HCT (20,485 (42.9%) allogeneic and 27,246 (57.1%) autologous) in 43,902 patients were reported by 696 European centers. 6042 patients received advanced cellular therapies, 4888 of which were CAR-T. Compared to the previous year there was an increase in CAR-T (+52.5%), in allogeneic HCT (+7.8%) but none in autologous HCT (+0.4%). Main indications for allogeneic HCT were myeloid (11,748; 60.7%), lymphoid malignancies (4,850; 25.0%), and non-malignant disorders (2558; 13.2%). Use of allogeneic HCT increased for AML (+12.1%) and for NHL (+11.0%), particularly in T-NHL (+25.6%). Main indications for autologous HCT were lymphomas (7890; 32.2%), PCD (14,271; 58.2%), and solid tumors (1608; 6.6%) with recovering numbers for autoimmune diseases. In patients with allogeneic HCT, the use of sibling donors increased by +1.0%, haploidentical donors by +11.7%, and unrelated donors by +11.1%. Cord blood HCT decreased again by −5.4%. Pediatric HCT activity increased slightly (5455; +0.1%) with differences between allogeneic (4111; −0.5%) and autologous HCT (1344: +1.7%). Use of CAR-T increased to a cumulative total of 13,927 patients including patients treated for autoimmune diseases. Overall, numbers show a complete recovery from the pandemic dip with increased cellular therapy at the expense of autologous HCT. Allogeneic HCT activity focuses on myeloid malignancies.

Abstract Image

查看原文本刊更多论文

2023年EBMT关于造血细胞移植和细胞治疗的报告。骨髓恶性肿瘤中异体HCT和CAR-T的使用增加，以牺牲自体HCT为代价。

2023年，696个欧洲中心报告了43,902例患者的47,731例HCT（20,485例（42.9%）异体和27,246例（57.1%）自体）。6042例患者接受了先进的细胞疗法，其中4888例为CAR-T疗法。与前一年相比，同种异体HCT的CAR-T增加（+52.5%），+7.8%，但自体HCT没有增加（+0.4%）。同种异体HCT的主要适应症是髓系(11,748例；60.7%)，淋巴细胞恶性肿瘤(4850；25.0%)，非恶性疾病(2558；13.2%)。同种异体HCT的使用增加了AML（+12.1%）和NHL(+11.0%)，特别是T-NHL（+25.6%）。自体HCT的主要适应症为淋巴瘤(7890；32.2%), PCD (14,271；58.2%)，实体瘤(1608；6.6%)，自身免疫性疾病的数量正在恢复。在异基因HCT患者中，兄弟姐妹供体的使用增加了+1.0%，单倍体供体增加了+11.7%，非亲属供体增加了+11.1%。脐带血HCT再次下降-5.4%。儿童HCT活动略有增加(5455；+0.1%)，异体(4111；-0.5%)和自体HCT（1344: +1.7%）。CAR-T的使用累计增加到13,927例患者，其中包括接受自身免疫性疾病治疗的患者。总体而言，数据显示，以牺牲自体HCT为代价，增加细胞治疗，可以从大流行低谷中完全恢复。同种异体HCT活动主要集中在髓系恶性肿瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bone Marrow Transplantation 医学-免疫学

CiteScore

8.40

自引率

8.30%

发文量

337

审稿时长

6 months

期刊介绍： Bone Marrow Transplantation publishes high quality, peer reviewed original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation. The broad scope of the journal thus encompasses topics such as stem cell biology, e.g., kinetics and cytokine control, transplantation immunology e.g., HLA and matching techniques, translational research, and clinical results of specific transplant protocols. Bone Marrow Transplantation publishes 24 issues a year.